New paper using Attana tecnology to understand how viruses enter human cells

We are happy to have been part of very important research project studying how a virus can infect human cells. In the paper “Crimean–Congo haemorrhagic fever virus uses LDLR to bind and enter host cells” Vanessa Monteil, Shane Wright, and co-workers at Karolinska Institutet shows how CCHF virus is able to enter cells using Low Density Lipoprotein Receptor (LDLR) and glycoproteins to obtain high affinity interactions between the virus and cells. Attana technology was used to determine affinity and kinetics of the interactions and to elucidate the role of different glycoproteins.

CCHF virus is primarily transmitted to humans via tick bites, but humans can also infect each other. Usually, infected individuals develop fever and pain, but in the worst case it can lead to organ failure and death. The current publication is part of a larger project to develop drugs against the virus, led by Docent Ali Mirazimi.

For more information, please contact:

Teodor Aastrup, CEO
ir@attana.com
+46 708 86 23 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com

Tags: